These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 18257513)

  • 21. 1‑calcium phosphate‑uracil, a synthesized pyrimidine derivative agent, has anti‑proliferative, pro‑apoptotic and anti‑invasion effects on multiple tumor cell lines.
    Peng J; Chen X; Hu Q; Yang M; Liu H; Wei W; Liu S; Wang H
    Mol Med Rep; 2014 Nov; 10(5):2271-8. PubMed ID: 25118659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton.
    Mashiach-Farkash E; Rak R; Elad-Sfadia G; Haklai R; Carmeli S; Kloog Y; Wolfson HJ
    Oncotarget; 2012 Jun; 3(6):629-39. PubMed ID: 22776759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic activities and DNA binding properties of 1-methyl-7H-indeno[1,2-b]quinolinium-7-(4-dimethylamino) benzylidene triflate.
    Li W; Ji YY; Wang JW; Zhu YM
    DNA Cell Biol; 2012 Jun; 31(6):1046-53. PubMed ID: 22277048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and antimicrobial activity of some new pyrazoles, fused pyrazolo[3,4-d]-pyrimidine and 1,2-dihydroimidazo-[2,1-c][1,2,4]triazin-6-one derivatives.
    Gomha SM; Hassaneen HM
    Molecules; 2011 Aug; 16(8):6549-60. PubMed ID: 21818058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.
    Santucci MA; Mancini M; Corradi V; Lacobucci I; Martinelli G; Botta M; Schenone S
    Invest New Drugs; 2010 Dec; 28(6):876-8. PubMed ID: 19629392
    [No Abstract]   [Full Text] [Related]  

  • 26. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
    Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
    Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.
    Radi M; Dreassi E; Brullo C; Crespan E; Tintori C; Bernardo V; Valoti M; Zamperini C; Daigl H; Musumeci F; Carraro F; Naldini A; Filippi I; Maga G; Schenone S; Botta M
    J Med Chem; 2011 Apr; 54(8):2610-26. PubMed ID: 21443205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.
    Carraro F; Naldini A; Pucci A; Locatelli GA; Maga G; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Modugno M; Tintori C; Manetti F; Botta M
    J Med Chem; 2006 Mar; 49(5):1549-61. PubMed ID: 16509573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells.
    Manetti F; Pucci A; Magnani M; Locatelli GA; Brullo C; Naldini A; Schenone S; Maga G; Carraro F; Botta M
    ChemMedChem; 2007 Mar; 2(3):343-53. PubMed ID: 17295370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
    Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
    Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.
    Manetti F; Brullo C; Magnani M; Mosci F; Chelli B; Crespan E; Schenone S; Naldini A; Bruno O; Trincavelli ML; Maga G; Carraro F; Martini C; Bondavalli F; Botta M
    J Med Chem; 2008 Mar; 51(5):1252-9. PubMed ID: 18257513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
    Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R
    Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.